-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PS87HOEG/+rX5VDWiQyMe5hD9ReDpH6wpSblWa7NHMZW7Zn43S7yfjAVG7MzVVAn Jl/3gbE0B1EZXcFrtPtrVQ== 0000000000-05-054658.txt : 20060828 0000000000-05-054658.hdr.sgml : 20060828 20051027131440 ACCESSION NUMBER: 0000000000-05-054658 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051027 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 514-332-32 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 PUBLIC REFERENCE ACCESSION NUMBER: 0000897069-05-001630 LETTER 1 filename1.txt Via Facsimile and U.S. Mail Mail Stop 6010 October 27, 2005 Mr. Roy Wolvin Chief Financial Officer Nymox Pharmaceutical Corporation 9900 Cavendish Blvd., Suite 306 St. Laurent, Quebec H4M 2V2 CANADA Re: Nymox Pharmaceutical Corporation Form 20-F for the Fiscal Year Ended December 31, 2004 Filed June 30, 2005 File No. 001-12033 Dear Mr. Wolvin: We have completed our review of your Form 20-F and have no further comments at this time. Sincerely, Jim Atkinson Accounting Branch Chief ?? ?? ?? ?? -----END PRIVACY-ENHANCED MESSAGE-----